Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Over the last two decades, the discovery of ketamine’s antidepressant properties has galvanized research into the neurobiology of treatment-resistant depression. Nevertheless, the mechanism of action underlying antidepressant response to ketamine remains unclear. This study reviews electrophysiological studies of ketamine’s effects in individuals with depression as well as healthy controls, with a focus on two putative markers of synaptic potentiation: gamma oscillations and long-term potentiation. The review focuses on: 1) measures of gamma oscillations and power and their relationship to both acute, psychotomimetic drug effects as well as delayed antidepressant response in mood disorders; 2) changes in long-term potentiation as a promising measure of synaptic potentiation following ketamine administration; and 3) recent efforts to model antidepressant response to ketamine using novel computational modeling techniques, in particular the application of dynamic causal modeling to electrophysiological data. The latter promises to better characterize the mechanisms underlying ketamine’s antidepressant effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Given that acute ketamine administration, even at subanesthetic doses, leads to transient dissociative and psychotomimetic effects that resemble the positive and negative symptoms of schizophrenia (Krystal et al., 1994), one potential hypothesis for this acute increase in gamma is that it reflects dysfunctions of cons…”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“, 1997), thereby activating neuroplasticity-related signaling pathways including mammalian target of rapamycin complex 1 (Li et al., 2010; Li et al., 2011) and brain-derived neurotrophic factor (Liu et al.”
BackgroundMechanisms of Gamma Oscillations
Buzsáki, G., & Wang, X.-J. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150444 · Cited by 2,796
Parvalbumin neurons and gamma rhythms enhance cortical circuit performance
Sohal, V. S., Zhang, F., Yizhar, O., & Deisseroth, K. (2009) · Nature · doi:10.1038/nature07991 · Cited by 2,606 · cited 1×
“In fact, this finding has been well-replicated across species, perhaps driven by reduced NMDA receptor-mediated input to fast-spiking parvalbumin-expressing GABAergic interneurons (Anver et al., 2011; Carlén et al., 2012; Hong et al., 2010; Lazarewicz et al., 2010; Maksimow et al., 2006; Sohal et al., 2009).”
BackgroundCollingridge, G. L., Kehl, S. J., & McLennan, H. (1983) · The Journal of Physiology · doi:10.1113/jphysiol.1983.sp014478 · Cited by 2,413
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“This synaptic potentiation and synaptogenesis has been posited to ultimately form the foundation of ketamine’s antidepressant effectiveness (Autry et al., 2011; Duman and Aghajanian, 2012; Nosyreva et al., 2013).”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 2×
“Due to NMDA receptor blockade on post-synaptic excitatory neurons, excess synaptic glutamate is primarily taken up by AMPA receptors (Duman et al., 2019; Moghaddam et al., 1997), thereby activating neuroplasticity-related signaling pathways including mammalian target of rapamycin complex 1 (Li et al.”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“This synaptic potentiation and synaptogenesis has been posited to ultimately form the foundation of ketamine’s antidepressant effectiveness (Autry et al., 2011; Duman and Aghajanian, 2012; Nosyreva et al., 2013).”
BackgroundWhittington, M. A., Traub, R. D., & Jefferys, J. G. R. (1995) · Nature · doi:10.1038/373612a0 · Cited by 1,613 · cited 1×
“Short-lived gamma frequency oscillations have been shown to emerge from the coordinated interaction of excitation and inhibition in modeling work (Brunel and Wang, 2003; Buzsáki and Wang, 2012; Economo and White, 2012; Ray and Maunsell, 2015) as well as in animal work (Csicsvari et al., 2003; Whittington et al., 1995).”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 2×
“Acute ketamine administration, which leads to pyramidal cell disinhibition downstream of NMDA receptor antagonism (Homayoun and Moghaddam, 2007; Widman and McMahon, 2018), should lead to robust changes in gamma oscillations.”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationDuman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026 · cited 2×
“…Balance Within psychiatry, a growing body of evidence suggests that alterations in the ratio of cortical excitation/inhibition balance could underlie a host of disorders, including depression (Fogaça and Duman, 2019; Fuchs et al., 2017; Godfrey et al., 2018; Kato et al., 2019).”
BackgroundDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 2×
“, 2006) and bipolar depression (Diazgranados et al., 2010; Zarate et al., 2012), including those who are treatment-resistant.”
BackgroundSelf-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 3×
“Early work examining the link between glutamatergic system dysfunction and depression focused on the role of NMDA receptor activation in long-term potentiation (LTP) in the hippocampus (Trullas and Skolnick, 1990), while more recent work has focused on ketamine’s specific role in enhancing LTP outside the hippocampus…”
BackgroundInfluentialNir, Y., Fisch, L., Mukamel, R., Gelbard-Sagiv, H., Arieli, A., Fried, I., & Malach, R. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.066 · Cited by 621 · cited 1×
“As an extension of this work, gamma rhythms have been found to be correlated with the generation of action potentials (Nir et al., 2007; Watson et al., 2018), suggesting that pharmacological interventions that increase gamma via synaptic potentiation might serve to alleviate depressive symptoms by increasing cortical…”
BackgroundFeder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 1×
“Studies have also observed rapid antidepressant effects following intranasal ketamine administration (Lapidus et al., 2014), which led the FDA to approve esketamine (the intranasally-administered S-enantiomer of ketamine) as a conjunctive treatment for treatment-resistant depression in 2019.”
BackgroundFava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433 · cited 12×
“Dynamic Causal Modeling of Ketamine Effects Authors Ketamine Dosage Time of measurement (acute or delayed) Study Sample Study Design/ Task Modality Regions Included Modeled Ketamine Effects Gilbert et al., 2018 Subanesthetic dose infusion Delayed effects measured 6 to 9 hours postinfusion HV, N=18 and MDD, N=18 Somato…”
BackgroundInfluentialPhillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418 · cited 1×
“Repeat infusions of ketamine have been shown to maintain ketamine’s antidepressant effects far beyond that of a single administration (Murrough et al., 2013b; Phillips et al., 2019).”
BackgroundLiu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Akil, H., & Watson, S. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.44 · Cited by 372
Fee, C., Banasr, M., & Sibille, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.024 · Cited by 329
Pinault, D. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.006 · Cited by 315 · cited 2×
“, 1994), one potential hypothesis for this acute increase in gamma is that it reflects dysfunctions of conscious integration, that is, the dissociative and psychotomimetic effects that occur during ketamine administration (Pinault, 2008).”
BackgroundKetamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283 · cited 1×
“This synaptic potentiation and synaptogenesis has been posited to ultimately form the foundation of ketamine’s antidepressant effectiveness (Autry et al., 2011; Duman and Aghajanian, 2012; Nosyreva et al., 2013).”
BackgroundDo the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 1×
“, 2019b); such studies have measured electrophysiological changes in gamma power during an antidepressant response window outside of ketamine’s acute, dissociative drug effects, which dissipate by about one hour post-infusion in most individuals (Luckenbaugh et al., 2014).”
BackgroundSelf-citationHong, L. E., Summerfelt, A., Buchanan, R. W., O'Donnell, P., Thaker, G. K., Weiler, M. A., & Lahti, A. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.168 · Cited by 274 · cited 3×
“In addition, acute ketamine administration has been found to decrease lowerfrequency oscillations, including delta (Hong et al., 2010) and theta (Lazarewicz et al.”
BackgroundKetamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects
Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0028-2 · Cited by 250
Self-citationWidman, A. J., & McMahon, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718883115 · Cited by 204
Fuchs, T., Jefferson, S. J., Hooper, A., Yee, P.-H., Maguire, J., & Luscher, B. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.188 · Cited by 204 · cited 2×
“Within psychiatry, a growing body of evidence suggests that alterations in the ratio of cortical excitation/inhibition balance could underlie a host of disorders, including depression (Fogaça and Duman, 2019; Fuchs et al., 2017; Godfrey et al., 2018; Kato et al., 2019).”
Background( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152
Self-citationKetamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., Jakubovski, E., & Bloch, M. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.194 · Cited by 142 · cited 2×
“…studies have also explored ketamine’s effectiveness in other clinical domains, including obsessive-compulsive disorder (Rodriguez et al., 2013), post-traumatic stress disorder (Feder et al., 2014), suicidal ideation (Murrough et al., 2015), and social anxiety disorder (Taylor et al., 2018).”
BackgroundKetamine amplifies induced gamma frequency oscillations in the human cerebral cortex
Shaw, A. D., Saxena, N., E. Jackson, L., Hall, J. E., Singh, K. D., & Muthukumaraswamy, S. D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.012 · Cited by 122 · cited 2×
“In both humans and animals, recent electrophysiological work found robust increases in gamma oscillations and measures of gamma power following acute ketamine administration at therapeutic, subanesthetic levels (de la Salle et al., 2016; Hong et al., 2010; Maksimow et al., 2006; Muthukumaraswamy et al., 2015; Shaw et…”
BackgroundEastwood, S. L., & Harrison, P. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.004 · Cited by 122
Modeling ketamine effects on synaptic plasticity during the mismatch negativity
Schmidt, A., Diaconescu, A. O., Kometer, M., Friston, K. J., Stephan, K. E., & Vollenweider, F. X. (2013) · Cerebral Cortex · doi:10.1093/cercor/bhs238 · Cited by 109 · cited 3×
“, 2015) as well as lower, antidepressant-level doses (Gilbert et al., 2018; Muthukumaraswamy et al., 2015; Rosch et al., 2019; Schmidt et al., 2012; Shaw et al., 2019; Sumner et al., 2019).”
BackgroundRosch, R. E., Auksztulewicz, R., Leung, P. D., Friston, K. J., & Baldeweg, T. (2019) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.07.003 · Cited by 56
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Antagonism of NMDARs on fast-spiking g-aminobutyric acid (GABA)-ergic interneurons inhibits interneuron tonic firing with a consequent glutamate surge (26).”
BackgroundSelf-citationKadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Self-citationKetamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Le, G. H., Wong, S., Badulescu, S., Au, H., Di Vincenzo, J. D., Gill, H., Phan, L., Rhee, T. G., Ho, R., Teopiz, K. M., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.165 · Cited by 30
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Metadata
- Authors
- Gilbert, J. R., & Zarate, C. A.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 189
- Pages
- 172856
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W2999453539
- Cited by
- 73
- References
- 44
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.